
==== Front
J Clin Transl Hepatol
J Clin Transl Hepatol
JCTH
Journal of Clinical and Translational Hepatology
2225-0719
2310-8819
XIA & HE Publishing Inc.

JCTH.2024.00019
10.14218/JCTH.2024.00019
Review Article
Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism
Feng X. et al: Mechanism of NAFLD
Feng Xiaoxi
Zhang Rutong
Yang Zhenye
Zhang Kaiguang *https://orcid.org/0000-0001-9462-6335

Xing Jun *https://orcid.org/0000-0002-2771-6725

Department of Digestive Disease, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
* Correspondence to: Jun Xing and Kaiguang Zhang, Department of Digestive Disease, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 17 Lujiang Road, Luyang District, Hefei, Anhui 230001, China. ORCID: https://orcid.org/0000-0002-2771-6725 (JX) and https://orcid.org/0000-0001-9462-6335 (KZ). E-mail: xingjunjoy@hotmail.com (JX) and zhangkaiguang@ustc.edu.cn (KZ).
This work was supported by the Research Start-up Funding for the First Affiliated Hospital of USTC (RC2021012) and the Fundamental Research Funds for Central Universities (WK9110000004).

The authors have no conflict of interests related to this publication.

XF and JX contributed to the writing of the first draft. RZ, ZY and KZ contributed to the correction and revision of the manuscript. All authors have approved the final version and publication of the manuscript.

28 9 2024
3 9 2024
12 9 815826
12 1 2024
02 8 2024
08 8 2024
© 2024 Authors.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, has a high global prevalence and can progress to metabolic dysfunction-associated steatohepatitis, cirrhosis, and hepatocellular carcinoma. The pathogenesis of MASLD is primarily driven by disturbances in hepatic lipid metabolism, involving six key processes: increased hepatic fatty acid uptake, enhanced fatty acid synthesis, reduced oxidative degradation of fatty acids, increased cholesterol uptake, elevated cholesterol synthesis, and increased bile acid synthesis. Consequently, maintaining hepatic lipid metabolic homeostasis is essential for effective MASLD management. Numerous novel molecules and Chinese proprietary medicines have demonstrated promising therapeutic potential in treating MASLD, primarily by inhibiting lipid synthesis and promoting lipid oxidation. In this review, we summarized recent research on MASLD, elucidated the molecular mechanisms by which lipid metabolism disorders contribute to MASLD pathogenesis, and discussed various lipid metabolism-targeted therapeutic approaches for MASLD.

Graphical abstract

MASLD
Lipid metabolism
Cholesterol metabolism
Lipogenesis
Lipolysis
lipid metabolism-targeted drugs
Chinese proprietary medicine
==== Body
pmcIntroduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a clinicopathological syndrome characterized by excessive fat deposition in hepatocytes that is not attributable to alcohol or other known liver-damaging factors. In 2023, non-alcoholic fatty liver disease was renamed MASLD following a Delphi consensus process. This renaming emphasizes the importance of metabolism in the disease and provides a more precise description. Consequently, we use the term MASLD instead of non-alcoholic fatty liver disease. MASLD is an acquired metabolic stress-associated liver injury closely related to insulin resistance and genetic susceptibility. It is one of the most common chronic diseases globally and a significant cause of liver injury in adults. The global prevalence of MASLD is approximately 29.8%.1 According to the National Health and Nutrition Examination Survey III, the prevalence of MASLD in the United States is 18.8%, rising to 28% in the overweight population.2 By 2018, the prevalence of MASLD in China had reached 32.9%, with the total population of MASLD in China expected to increase to 314.58 million people by 2030.3

The development of MASLD is closely linked to genetic alterations and environmental influences. The risk factors can be divided into genetic, epigenetic, and environmental factors.4 Genetic factors include mutations in genes such as I148M PNPLA3, TM6SF2, MBOAT7, and GCKR, which increase susceptibility to MASLD.5 Epigenetic factors include DNA methylation, chromatin remodeling, and non-coding RNAs. For instance, the M6A “writer” protein methyltransferase-like 3 ameliorates MASLD via RNA methylation.6 Additionally, replication protein A1 can maintain lipid metabolism homeostasis and thus ameliorate MASLD by regulating chromatin structure.7 Many non-coding RNAs involved in the regulation of lipid metabolism, such as miR-34a, miR-122, and miR-21, play a role in the development of MASLD.8 Furthermore, environmental factors play a critical role in the progression of MASLD. These include dietary habits, exercise status, and socioeconomic factors. Unhealthy dietary habits, such as high sugar and fat consumption,9 sedentary lifestyles, and infrequent exercise,10,11 increase susceptibility to MASLD.

MASLD can be classified as simple steatosis or metabolic dysfunction-associated steatohepatitis (MASH). MASH is characterized by pathological histological lobular inflammation and ballooning of hepatocytes attributable to MASLD. Prolonged liver injury can lead to cirrhosis and hepatocellular carcinoma (HCC). A common clinical method to diagnose MASLD is the detection of hepatic fat density on MRI.12 Additionally, plasma cytokeratin 18, a marker of hepatocyte apoptosis, has been widely used to assess MASLD.13 In recent years, mutations in the PNPLA3 and TM6SF2 genes have been shown to correlate with the severity of MASLD, highlighting their potential as new diagnostic markers. Furthermore, autophagy-related markers, oxidative stress-related markers, inflammatory factors, and liver fibrosis-related markers can also be used to assess the progression of MASLD.

Many treatments have been developed for MASLD. First, dietary control and appropriate exercise habits can significantly alleviate MASLD. Second, glucagon-like peptide-1 (GLP-1) agonists, sterol-regulatory element binding protein (SREBP) inhibitors, acetyl-CoA carboxylase (ACC) inhibitors, fatty acid synthase (FASN) inhibitors, stearoyl coenzyme A desaturase (SCD) inhibitors, farnesoid X receptor (FXR) agonists, peroxisome proliferator-activated receptor (PPAR) agonists, and certain natural compounds are considered promising treatments. In recent years, there has been tremendous growth in research focused on treating MASLD by modulating lipid metabolism, with an increasing number of drugs in clinical development. However, the treatment of MASLD remains challenging due to population selection issues and the side effects of current drugs. Given the crucial role of lipid metabolism in MASLD, exploring new drugs and targets for lipid metabolism modulation has become a popular direction for treatment research.

Lipid metabolism

Lipids serve as crucial energy sources in the body, and various molecules involved in lipid metabolism play integral roles in different cellular functions. The development of MASLD is closely related to lipid metabolism, particularly the metabolism of triglycerides and cholesterol. Triglycerides are synthesized from fatty acids. In this review, we primarily focus on fatty acid and cholesterol metabolism. The maintenance of hepatic lipid metabolic homeostasis involves three aspects: uptake, synthesis, and catabolism. It is widely believed that an increase in fatty acid uptake and synthesis or a decrease in lipid degradation leads to the development of MASLD. Therefore, researchers have increasingly focused on these aspects, and various viewpoints have been proposed.

Fatty acid metabolism

Fatty acid intake

The hepatic uptake of fatty acids depends on fatty acid transport carriers, including fatty acid transport proteins (FATPs), cluster of differentiation 36 (CD36), and hepatic caveolin-1 (CAV-1).

FATPs

Six FATP isoforms have been identified, with FATP2 and FATP5 primarily found in the liver.14 These transport proteins play crucial roles in the development of MASLD. Downregulation of FATP2 in mice reduces fatty acid uptake and ameliorates hepatic steatosis induced by a high-fat diet.15 Deletion of FATP2 in the mouse liver alters the metabolic landscape by increasing the expression of PPARα-regulated genes.16 Knockdown of FATP5 leads to reduced hepatic fatty acid uptake, which in turn decreases hepatic lipid accumulation.17 However, decreased hepatic FATP5 expression is associated with the histological progression of MASLD, which might be related to the reduction of hepatic lipid content as MASH advances to cirrhosis.18 Thus, FATP5 might have a dual role in the development of MASLD.

CD36

Experiments have confirmed the involvement of CD36 in hepatic fatty acid uptake and lipid accumulation.19 CD36 palmitoylation is an important factor in the pathogenesis of MASLD. In vitro and in vivo studies have demonstrated that inhibiting CD36 palmitoylation can ameliorate fatty acid metabolism disorders and reduce inflammatory reactions.20 Inhibition of CD36 palmitoylation also attenuates MASLD by promoting CD36 localization to hepatocyte mitochondria.21 The palmitoyltransferases DHHC4 and DHHC5 promote fatty acid uptake by targeting CD36.22 Several upstream factors regulating CD36 are also involved in MASLD. Demethylation of the PPARγ DNA promoter increases CD36 expression, leading to excessive lipid accumulation.23 Hepatic Dickkopf-1 enhances fatty acid uptake through the ERK–PPARγ–CD36 axis.24 Deletion of methyltransferase-like 3 in hepatocytes increases CD36 expression and hepatic free fatty acid uptake, promoting MASH development. Hypoxia-inducible factor 1α interacts with the CD36 promoter to increase CD36 expression and enhance fatty acid uptake.25 Additionally, non-coding RNAs such as miR-96-5p,26 miR-100,27 miR-26a,28 and miR-195/miR466829 regulate CD36 expression and affect the development of MASLD.

CAV-1

The role of CAV-1 in the development of MASLD remains controversial due to its role in mediating lipid endocytosis. Although some studies have detected increased CAV-1 expression in the liver tissue of mice with MASLD-fed high-fat diets, others have found a significant reduction in its expression in mice with MASLD.30 Knockdown of CAV-1 in LO2 and AML12 cells resulted in increased steatosis.31 CAV-1 upregulation has been found to attenuate lipid accumulation and promote autophagy in mice with MASLD.32 Interestingly, hepatocyte-specific CAV-1 knockdown significantly altered the gene profile in the development of MASLD without affecting hepatic steatosis and fibrosis.33

De novo fatty acid synthesis

De novo fatty acid synthesis is a process by which the body converts carbon from carbohydrates, such as glucose, and amino acids, including glutamine, into fatty acids. The raw material for de novo fatty acid synthesis is acetyl-CoA, which is derived from two sources. First, acetyl-CoA in mitochondria is condensed with oxaloacetate, catalyzed by citrate synthase, to form citric acid, which is then transported to the cytosol by tricarboxylic acid transport proteins in the mitochondrial membrane. Citric acid is subsequently modified by ATP citrate lyase (ACLY) to regenerate acetyl-CoA, which is used for fatty acid synthesis. This process is called the citrate shuttle. Second, acetic acid is linked to coenzyme A to synthesize acetyl-CoA, providing additional raw material for fatty acid synthesis, catalyzed by acetyl-CoA synthetase (ACSS). The generated acetyl-CoA is initially converted to malonyl coenzyme A by ACC, the key rate-limiting step. Malonyl coenzyme A is then converted to palmitic acid via FASN. Saturated palmitic acid (FA16:0) can undergo C-chain extension and desaturation by SCD to produce other fatty acid species. These fatty acids can be used to generate more complex lipids. The key enzymes involved in de novo fatty acid synthesis play important roles in the development of MASLD (Fig. 1).

Fig. 1 Fatty acid metabolism. Fatty acid uptake by the liver depends on fatty acid transport carriers, including FATP, CD36, and CAV-1.

The raw material for de novo fatty acid synthesis is acetyl-CoA, which can be obtained via the citrate shuttle pathway or from acetic acid. ACC and FASN catalyze the conversion of acetyl-CoA into saturated palmitic acid, which can be further modified into other fatty acids by enzymes such as SCD. De novo fatty acid synthesis is promoted by SREBPs. Conversely, the β-oxidation of fatty acids occurs in the mitochondria. Fatty acids are converted into fatty acyl-CoA by ACSL and transported via CPT-1 before being oxidized to acetyl-CoA. Fatty acid β-oxidation is promoted by PPARα. FAs, fatty acids; FASN, fatty acid synthase; SREBP, sterol-regulatory element binding protein; FASN, fatty acid synthase; ACC, acetyl-CoA carboxylase; ACLY, ATP citrate lyase; ACSS, acetyl-CoA synthetase; ACSL, acyl-CoA synthetase; PPAR, peroxisome proliferator-activated receptor; CPT-1, carnitine palmitoyltransferase-1.

SREBPs play critical roles in the development of MASLD by transcriptionally regulating key genes involved in hepatic lipid metabolism. SREBPs are divided into SREBP1 and SREBP2. SREBP1 has two transcripts, SREBP1a and SREBP1c, with SREBP1c being more widely expressed. SREBP1a is expressed in the intestinal epithelium, heart, and macrophages, while SREBP2 is primarily expressed in hepatic and adipose tissue. SREBPs can form trimers with SREBP cleavage-activating protein (SCAP) and INSIG, anchoring the protein in the endoplasmic reticulum (ER). The C-terminal region of SCAP interacts with the C-terminal structural domain of the ER, while the N-terminal region of SCAP contains a sterol-sensing domain sensitive to cholesterol levels. When cholesterol levels are high, SCAP binds with cholesterol and INSIG, resulting in the retention of the entire complex in the ER. Conversely, when cholesterol levels decrease, SCAP does not interact with INSIG, allowing the SREBP–SCAP complex to be internalized into COPII-containing vesicles, which are transported to the Golgi apparatus. Within the Golgi, SREBPs are sequentially cleaved by site-1 protease and site-2 protease, releasing their N-terminal bHLH structural domain into the cytoplasm, where it acts as a transcription factor. The bHLH structural domain migrates to the nucleus, dimerizes, and forms a complex with transcriptional co-activators, activating the transcription of genes with SRE motifs. SREBP1 mainly regulates fatty acid synthesis and LDLR expression, while SREBP2 primarily regulates the expression of cholesterol biosynthetic genes.

ACLY and ACSS

Inhibiting ACLY can reduce hepatic lipid accumulation by suppressing de novo fatty acid synthesis. Recent research has clarified the involvement of ACLY in MASLD. In steatotic cells, ACLY mRNA is efficiently translated in a cap-independent manner, promoting adipogenesis.34 The sirtuin 2–ACLY axis is also involved in MASLD progression, with sirtuin 2 inhibiting ACLY and lipid accumulation.35 Additionally, ACLY is degraded by HMG-CoA reductase degradation protein via ubiquitination, thereby attenuating MASLD.36 ACSS is involved in the synthesis of acetyl-CoA, which promotes hepatic steatosis. Silencing ACSS2 can effectively inhibit the conversion of fructose to acetyl-CoA and fatty acids in mice.37

ACC

ACC, a key enzyme in de novo fatty acid synthesis, plays a significant role in MASLD development. Liver-specific ACC1 knockdown reduces hepatic lipid accumulation and impairs hepatocyte de novo fatty acid synthesis in mice.38 AMPK activates the phosphorylation of ACC1 (Ser79Ala) and ACC2 (Ser212Ala), inhibiting the enzymatic activity of ACC and thereby suppressing lipid synthesis. Mutations at these sites are associated with increased de novo fatty acid synthesis and steatosis in the liver.39

FASN and SCD

FASN and SCD are markers of lipid synthesis and are both upregulated in MASLD. FASN regulation plays an important role in MASLD. Sorting nexin 8 can prevent MASLD by promoting FASN degradation, making the sorting nexin 8–FASN axis a promising target for MASLD prevention and treatment.40 miR-103 can also inhibit hepatic steatosis by targeting FASN and SCD1, which can attenuate MASLD.41 Slug binds to the FSAN promoter, while Slug-associated LSD1 catalyzes H3K9 demethylation, stimulating FASN expression and lipogenesis.42 Furthermore, in MASLD, the levels of mitochondrial pyruvate carrier 1 are positively correlated with hepatic lipid deposition, and mitochondrial pyruvate carrier 1 knockdown affects FASN lactylation at K673, ultimately inhibiting FASN activity.43

SREBP1

SREBP1c induces the expression of ACC, FASN, and SCD, promoting hepatic fatty acid and triglyceride synthesis. Increased SREBP1 expression is observed in patients with MASLD, and SREBP1c overexpression in mice increases hepatic triglyceride levels.44 However, exercise and strength training can reduce hepatic lipid accumulation by downregulating SREBP1.45,46 Activated AMPK phosphorylates SREBPs, reducing their activity and inhibiting hepatic lipid accumulation. VEGFB,47 MD2,48 and protectin DX49 are involved in MASLD development through the AMPK–SREBP1 pathway. mTOR promotes the maturation and nucleation of SREBP1, enhancing lipid synthesis.50 Pancreatic progenitor cell differentiation and proliferation factor reduces hepatic steatosis by inhibiting mTOR/SPRBP1.51 CD36 promotes de novo lipogenesis through INSIG2-dependent SREBP1 hydrolytic processing.52 Additionally, non-coding RNAs including miR-23a/b-3p,53 miR-33-5p,54 and miR-130b-5p55 regulate SREBP1 expression. ZBTB7A,56 ceramide synthase,57 and dihydroxytryptamine58 are believed to upregulate SREBP1, promoting lipid synthesis. Interestingly, although SREBP1a does not contribute to hepatic lipogenesis, its absence in hepatocytes or macrophages exacerbates methionine- and choline-deficient diet-induced MASLD.59

SREBP2

The high-fat, choline-deficient, amino acid-defined diet model is a newly established mouse model of MASH that activates the SREBP2/SCD2 gene and drives liver fibrosis through high-fat feeding.60 The expression of SCD, FASN, and SREBP2 is increased in rats fed a Western diet.61 Moreover, SREBP2 is regulated by the AMPK signaling pathway, and increased expression of SREBP2 alleviates autophagic dysfunction in MASLD.62

Fatty acid β-oxidation

Fatty acid oxidation refers to the process by which fatty acids are degraded in the presence of oxygen to release energy for various biological processes. The most common pathway is the β-oxidation of fatty acids. β-oxidation of long-chain fatty acids occurs in the mitochondria, whereas very-long-chain fatty acids are oxidized in peroxisomes. Mitochondrial β-oxidation consists of three steps. First, fatty acids are activated to fatty acyl-CoA, a reaction catalyzed by acyl-CoA synthetase (ACSL). Second, while the enzyme system catalyzing fatty acid β-oxidation is located in the mitochondrial matrix, long-chain fatty acyl-CoA requires a carrier, namely carnitine palmitoyltransferase-1 (CPT-1), to be transported through the inner mitochondrial membrane. Finally, the β-oxidation of fatty acyl-CoA in the mitochondrial matrix proceeds through a four-step reaction involving dehydrogenation, hydration, re-dehydrogenation, and thiolysis, ultimately producing one molecule of acetyl-CoA and a new molecule of fatty acyl-CoA with two fewer carbons. This cycle repeats several times to gradually produce more acetyl-CoA. Peroxisomal β-oxidation is similar to mitochondrial β-oxidation, but the first step is catalyzed by lipid acyl-CoA oxidase (Fig. 1).

The PPAR system, particularly PPARα, plays an important role in the regulation of lipid metabolism. Activated PPARs form heterodimers with the retinoid X receptor and bind to peroxisome proliferator-responsive elements upstream of certain genes to activate enzymes related to lipid metabolism. PPARα has various roles in lipid metabolism, including promoting fatty acid β-oxidation and inhibiting MASLD development.

ACSL

TANK-binding kinase 1 acts as a scaffolding protein to localize ACSL1 to mitochondria and promote fatty acid oxidation.63 Although ACSL4 is weakly expressed in the liver, it is upregulated in patients with MASLD, which contradicts the conventional belief that ACSL4 promotes fatty acid β-oxidation and inhibits MASLD.64 This might be attributable to ACSL4’s ability to promote inflammation65 and its involvement in ferroptosis.66 Additionally, P115 interacts with ACSL4 and degrades it. P115 is significantly upregulated in the livers of high-fat diet-fed mice, resulting in the downregulation of ACSL4 protein.67 ACSL5 knockdown in mice increases energy expenditure and insulin sensitivity and delays fat absorption.68

CPT-1

Exercise can lead to CPT-1 downregulation, thereby reducing the disruption of lipid metabolism in MASLD.69,70

PPARα

Metabolomic and lipidomic screening revealed that PPARα plays an important role in the progression of MASH to HCC.71 In a mouse model, obese female offspring fed a high-fat diet exhibited impaired hepatic PPARα activation.72 Moreover, PPARα is sex-selective, making male mice more susceptible to MASLD.73 Mechanistically, PPARα can reduce hepatic steatosis by rebuilding the intestinal barrier and regulating the distribution of the intestinal flora.74 Intestinal PPARα in mice with MASLD can promote MASH progression by regulating fatty acid uptake.75 Several molecules can also affect MASLD by influencing PPARα. For example, the anti-adipogenic factor coenzyme Q10 regulates MASLD by upregulating PPARα and CPT-1.76 Programmed cell death 4,77 obesity-associated protein,78 and mothers against decapentaplegic homolog family member 479 promote hepatocyte lipid deposition by inhibiting PPARα-mediated fatty acid oxidation.

Cholesterol metabolism

Cholesterol uptake

The uptake of dietary cholesterol by intestinal epithelial cells is facilitated by Niemann–Pick type C1-like 1 (NPC1L1). The accumulated cholesterol is then esterified by cholesterol acyltransferases, also known as sterol O-acyltransferases, for hepatic uptake.80

NPC1L1

Expression of the human NPC1L1 gene in the mouse liver exacerbates high-fat diet-induced steatosis.81,82

Cholesterol synthesis

Cholesterol synthesis originates from acetyl-CoA through a complex process involving nearly 30 enzymatic steps. This process can be roughly divided into three stages: synthesis of isopentenyl pyrophosphate from acetyl-CoA, synthesis of squalene, and conversion of squalene to cholesterol (Fig. 2). The key enzymes involved in this process are mammalian 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase (HMGCR/HMFR) and squalene monooxygenase (SM/SQLE). HMGCR catalyzes the conversion of HMG-CoA to mevalonate in the first phase, while squalene is oxidized by SM in the third stage to produce 2,3-oxidized squalene, a precursor of cholesterol and sterols.

Fig. 2 Cholesterol metabolism.

The process of cholesterol synthesis is complex and can be roughly divided into three stages: synthesis of IPP from acetyl-CoA, synthesis of squalene, and conversion of squalene to cholesterol. HMGCR and SM are the key enzymes in cholesterol synthesis. The primary route of cholesterol production is bile acid synthesis catalyzed by CTP7A1. FXR is an important regulator of cholesterol metabolism; Its activation inhibits CTP7A1, leading to the inhibition of bile acid synthesis. FXR, farnesoid X receptor; CYP7A1, cholesterol 7α-hydroxylase; SM, squalene monooxygenase; HMGCR, 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase; IPP, isopentenyl pyrophosphate; SREBP, sterol-regulatory element binding protein; PPAR, peroxisome proliferator-activated receptor; FAs, fatty acids; ACC, acetyl-CoA carboxylase; FASN, fatty acid synthase; ACLY, ATP citrate lyase.

HMGCR

Dysregulated cholesterol metabolism can exacerbate MASLD. The development of MASLD is associated with increased HMGCR expression and reduced HMGCR phosphorylation.83 A genomic analysis of a high-fat-fed mouse model of MASLD showed a 2.06-fold upregulation of HMGCR.84 HMGCR is regulated by Dicer1/miR-29, indicating that the Dicer1–miR-29–HMGCR axis is involved in free cholesterol accumulation in the livers of mice with MASLD.85

SM/SQLE

SM/SQLE is implicated in the progression of MASLD to HCC. It is the most significantly overexpressed metabolic gene in patients with MASLD and HCC, and its expression accelerates the development of HCC induced by a high-fat, high-cholesterol diet in mice.86–88 The underlying mechanisms include the promotion of MASH and HCC development through the induction of cholesterol biosynthesis, the SQLE–CA3 axis-mediated lipogenesis,88 and P53-mediated transcriptional regulation of SQLE to suppress cholesterol synthesis and tumor growth.89

Bile acid synthesis

Bile-acid synthesis is the primary pathway for cholesterol catabolism, and the key enzyme in this process is cholesterol 7α-hydroxylase (CYP7A1). Patients with MASLD often exhibit disordered bile acid metabolism. Hepatic bile acid synthesis is mainly regulated by FXR, and FXR activation inhibits de novo bile acid synthesis (Fig. 2).

CYP7A1

Bioinformatic analysis has revealed that CYP7A1 is involved in the development of MASLD, MASH, and HCC.90,91 In MASLD, CYP7A1 mRNA expression is increased.92 However, CYP7A1 mRNA levels decline with the progression of MASH-associated liver fibrosis.93

FXR

FXR plays a crucial role in the development of MASLD. On one hand, FXR activation promotes the production of short heterodimer partner, which downregulates the rate-limiting enzyme CYP7A1, ultimately inhibiting bile acid synthesis. Studies have demonstrated that FXR activation can prevent MASLD by reducing lipid uptake in a bile acid-dependent manner.94 On the other hand, FXR activation decreases hepatic lipid accumulation by inhibiting triglyceride synthesis, achieved through the induction of short heterodimer partner expression and the downregulation of SREBP1 and FASN.

FXR deficiency in mice results in hepatic steatosis, lipid droplet accumulation in hepatocytes, disturbed glucose metabolism, and elevated blood lipid levels.95 FXR functions as a nuclear transcription factor that regulates glucose and lipid metabolic homeostasis through pyruvate dehydrogenase kinase 4.95 Furthermore, FXR sulfation, a post-translational modification influenced by endogenous hepatic cystathionine γ lyase/hydrogen sulfide, promotes FXR activity, thereby improving MASLD.96 MiR-552-3p ameliorates hepatic lipid metabolism disorders by regulating the transcriptional activity of FXR.97

Drugs that treat MASLD by regulating lipid metabolism

The FDA has approved Rezdiffra (resmetirom), a thyroid hormone receptor β-1 agonist, as the first treatment for MASH. Resmetirom selectively activates thyroid hormone receptor β-1, resulting in a reduction of free thyroxine (T4) levels by approximately 16–19%. Notably, it does not influence the levels of thyrotropin or free triiodothyronine.98 Resmetirom also significantly reduces cholesterol and triglyceride levels and enhances fatty acid oxidation, demonstrating substantial potential for the treatment of MASLD. Meanwhile, there has been increasing interest in developing new drugs for MASLD treatment. In this section, we review recent articles exploring molecular drugs and Chinese proprietary medicines (CPMs) that inhibit MASLD. Most of these drugs/CPMs work by inhibiting fatty acid uptake and synthesis while promoting fatty acid oxidation. Similarly, the inhibition of cholesterol uptake and synthesis, as well as bile acid synthesis, can also be used to improve MASLD. CPMs have shown great potential in MASLD treatment. The modification of inhibitors and activators targeting key regulatory genes, such as GLP-1, SREBP, ACC, FASN, SCD1, PPARα, and FXR, has gained increasing attention in recent years. Improving the therapeutic efficacy of drugs and reducing their potential side effects have become major research goals in this field.

GLP-1 agonists

GLP-1 regulates insulin and glucagon secretion and modulates intestinal motility, and its agonists have been considered promising therapeutics in recent years for reducing the risk of MASLD and its associated mortality.99 GLP-1 agonists, such as semaglutide and liraglutide, effectively treat MASLD by reducing visceral and hepatic fat content.100–102 Semaglutide improves the health-related quality of life in patients with MASLD,103 with daily dosing proving more effective.104 Mechanistically, semaglutide induces modifications in the gut microbiota and ameliorates MASLD.105 Dual GLP-1/GLP-2 receptor agonists,106 as well as dual GLP-1 receptor/glucagon receptor agonists like ALT-801, NN1177, and efinopegdutide,107–109 have shown good therapeutic efficacy in MASLD. The combination of GLP-1 activators with other drugs is also the focus of an increasing number of studies. Combined treatment with semaglutide and the FXR agonist cilofexor, the ACC inhibitor firsocostat, and the ACLY inhibitor has demonstrated better therapeutic efficacy than monotherapy.110,111 Novel GLP-1 activators, such as cinchonine and exendin-4, are also under development.112,113

The findings of clinical trials on GLP-1 agonists are listed in Table 1.103,107,114-122 “\” indicates that no phasing information for the clinical trial could be found.

Table 1 Clinical trials of GLP-1 agonists

Drugs	Conclusions	Phase	References	
Dulaglutide	Improvement in patients with type 2 diabetes and MASLD	\	114	
Efinopegdutide	Improvement of MASH and MASLD	Phase II	107	
Exenatide	Improvement in patients with type 2 diabetes and MASLD	\	115	
Liraglutide	Improvement of MASH and MASLD	Phase II/III	116–118	
	Improvement in patients with type 2 diabetes and MASLD	Phase IV	119	
	No improvement in patients with type 2 diabetes and MASLD	Phase IV	120	
Semaglutide	Improvement of MASH but not liver fibrosis	Phase I/II	121,122	
	Improvement of health-related quality of life in patients with MASH and liver fibrosis	Phase II	103	
MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis.

SREBP inhibitors

Betulin is a specific inhibitor of SREBP maturation. It inhibits the transport of SREBP to the Golgi via SCAP,52 thereby inhibiting the processes of fatty acid and cholesterol synthesis. Betulin has shown potential in the treatment of MASLD.123–126 PF-429242 is a specific inhibitor of the proteasome site-1 protease, which inhibits the cleavage and release of the SREBP precursor protein. It is also considered to have potential in MASLD control.127

ACC inhibitors

ACC inhibition reduces lipid accumulation in hepatocytes and inhibits pro-fibrosis activity in liver stem cells, suggesting that small-molecule inhibitors of ACC can attenuate liver fibrosis by reducing hepatocyte lipotoxicity and preventing liver stem cell activation. These findings provide a mechanistic basis for the treatment of patients with MASH and advanced liver fibrosis.128 However, while ACC inhibitors have been found to reverse MASLD, they may also promote hypertriglyceridemia.129 GS-0976 (Firsocostat) has shown promise in alleviating MASH in Phase II clinical trials.130,131 However, firsocostat can cause hyperlipidemia, which can be alleviated by fenofibrate.132,133 The ACC inhibitor ND-654, which mimics the action of ACC phosphorylation, inhibits hepatic de novo fatty acid synthesis.39 In mouse models, treatment with selective ACC1 inhibitors significantly ameliorated hepatic steatosis and liver fibrosis, supporting their use as new therapies for MASLD/MASH.134 Additionally, both the dual ACC1/ACC2 inhibitor PF-05221304135 and the novel ACC1/ACC2 inhibitor WZ66136 have been shown to alleviate MASH in mouse models.

FASN or SCD1 inhibitors

In patients with MASLD, FASN inhibitors such as TVB-2640 (Denifanstat)137 and FT-4101138 reduce hepatic de novo lipogenesis and steatosis. FASstatin may be useful in treating MASLD by targeting and degrading FASN.139 Both the SCD1 inhibitor CAY10566 and a novel SCD1 inhibitor have inhibited hepatic lipid accumulation in mice, suggesting that SCD1 may be an effective target for the treatment of MASLD.140,141

PPAR agonists

Fibrates are clinically available PPARα agonists for MASLD treatment. The literature indicates that PPARα-mediated peroxisome adaptation is crucial for fenofibrate-mediated improvements in MASLD.142 Combining PPARα with other dual-receptor agonists has shown great potential in MASLD treatment. The novel PPARα/γ agonists G4 and G5 effectively inhibited hepatic steatosis while avoiding the side effects of pioglitazone.143 The PPARα/γ agonist aleglitazar significantly reduced hepatic steatosis and fibrosis.144 The PPARα/δ agonist compound H11, which exhibits effective and balanced PPARα/δ agonist activity, has shown promise in MASH treatment.145 Additionally, ZLY18, a quadruple free fatty acid receptor 1 and PPARα/γ/δ agonist, might be a highly effective anti-MASLD drug.146

The findings of the clinical trials on PPAR agonists are listed in Table 2.144,147–150 “\” indicates that no phasing information for the clinical trial could be found.

Table 2 Clinical trials of PPAR agonists

Drugs	Targets	Conclusions	Phase	References	
Aleglitazar	PPARα/γ	Improvement of MASLD and liver fibrosis	\	144	
Elafibranor	PPARα/δ	Improvement of MASH	Phase II	147	
Lanifibranor	Pan-PPAR	Improvement of MASH and liver fibrosis	Phase III	148	
Saroglitazar	PPARα/γ	Improvement of MASH and MASLD	Phase II	149,150	
PPAR, peroxisome proliferator-activated receptor; MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis.

FXR agonists

Although traditional FXR agonists have been used in the clinic, their side effects have limited their application to some extent. The traditional FXR agonist, obeticholic acid, has been abandoned for MASLD treatment. New FXR agonists, such as nidufexor (LMB763),151 cilofexor,152 and EDP-305,153 have entered clinical trials for the treatment of MASLD or MASH. In recent years, the development of FXR agonists with stronger activity and fewer side effects has received increasing attention. For instance, 1-adamantylcarbonyl-4-phenylpiperazine is an FXR agonist, and its derivative compound 10A was found to be more effective in ameliorating hyperlipidemia, hepatic steatosis, and insulin resistance.154 Additionally, structural optimization of non-bile acid FXR agonists led to the development of compound 42 as an FXR agonist with high efficiency and selectivity for alleviating MASH.155 MET409, an FXR agonist with a unique chemical structure, significantly suppressed hepatic fat content without causing significant or severe side effects in patients with MASH.156 Moreover, tissue-selective FXR agonists have been studied. For example, (E)-3-(3-((2-cyano-4′-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl) acrylic acid methyl ester is an entero-selective FXR partial agonist that significantly reduced the extent of liver fibrosis and decreased the levels of fibrosis markers and serum AST.157 BMS-986339 exhibited potent FXR activation and anti-fibrotic efficacy despite its tissue selectivity, reducing the activation of certain genes in the liver.158

The findings of the clinical trials on FXR agonists are listed in Table 3.152,156,159–162

Table 3 Clinical trials of FXR agonists

Drugs	Conclusions	Phase	References	
Cilofexor	Improvement of MASH	Phase II	152,159	
MET409	Improvement of MASH	Phase I	156	
Obeticholic acid	Improvement in patients with type 2 diabetes and MASH	Phase II	160	
Tropifexor	Improvement of MASH	Phase II	161	
Vonafexor	Improvement of liver and kidney function in patients with MASH and liver fibrosis	Phase II	162	
MASH, metabolic dysfunction-associated steatohepatitis.

Natural compounds

Many natural compounds, including CPMs, are considered promising in the treatment of MASLD. Recent studies on natural compounds and their molecular mechanisms are listed in Table 4.163–187 However, the use of many CPMs for the treatment of MASLD still needs to be tested in rigorous clinical trials. Nevertheless, CPMs remain a valuable resource in modern medicine and have significant potential for the future treatment of MASLD.

Table 4 Drugs that treat MASLD by regulating lipid metabolism

Drugs	Mechanism	References	
Andrographolide	Inhibits FATP2	163	
Baicalein	Inhibits fatty acid synthesis; promotes fatty acid oxidation; activates AMPK; inhibits SREBP1	164,165	
Berberine/oxyberberine	Inhibits fatty acid synthesis; promotes fatty acid oxidation; regulates SIRT3/AMPK/ACC; downregulates SIRT1/FoxO1/SREBP2; inhibits cholesterol synthesis	166–170	
Curcumin	Inhibits CD36, SLC13A5, and ACLY; regulates CYP2E1, SREBP1c, and PPARα	171–173	
Extract of Dillenia indica L.	Regulates SIRT1/pLKB1/AMPK, HMGCR, and PPARα signaling pathways	174	
Extract of Liriope platyphylla	Inhibits fatty acid uptake and synthesis	175	
Extract of root from Arctium lappa L.	Activates AMPK/ACC/CPT1	176	
Jian Pi Qing Gan Yin decoction	Activates AMPK/PPARα; inhibits LXRα/SREBP1/NF-κB	177	
Kangtaizhi Granule	Regulates PPARγ, SREBP1, pAKT, FAS, and SIRT1	178	
Limonin	AMPK agonist; downregulates FASN and SREBP1	179,180	
Naringenin	Activates the CaMKKβ/AMPK/ACC pathway	181	
Paeoniflorin	Activates LKB1/AMPK and PPARα	182,183	
Puerarin	Inhibits fatty acid uptake and synthesis; promotes fatty acid oxidation; inhibits FASN, SREBP1c; activates AMPK	184,185	
Saikosaponin	Inhibits SREBP1c; activates PPARα; inhibits FASN; promotes ACOX1 and CPT1	186,187	
FATP, fatty acid transport protein; AMPK, AMP-activated protein kinase; SREBP, sterol regulatory element-binding protein; ACC, acetyl-CoA carboxylase; ACLY, ATP citrate lyase; PPAR, peroxisome proliferator-activated receptor; HMGCR, 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase; CPT1, carnitine palmitoyltransferase-1; FASN, fatty acid synthase.

Discussion

MASLD represents a continuum of liver diseases that includes simple steatosis and metabolic dysfunction-associated steatohepatitis. The global prevalence of MASLD is estimated to be as high as 29.8%, making it one of the most significant diseases. Most patients with MASLD are asymptomatic and only present with incidental findings of hepatomegaly or slight-to-moderate increases in ALT and AST levels during routine physical examinations. The current primary approach for treating MASLD is reducing hepatic steatosis by regulating lipid metabolism. Dietary control and appropriate exercise can significantly improve the symptoms of MASLD. Additionally, drugs such as FXR agonists, PPARα agonists, and SREBP1 inhibitors have been explored for MASLD treatment because of their ability to regulate lipid metabolism.

The pathology of MASLD is characterized by hepatic steatosis, the development of which is mainly related to dysregulated hepatic lipid metabolism. The development of MASLD is generally attributed to six factors: increased hepatic fatty acid uptake and synthesis, decreased fat oxidation, increased cholesterol uptake and synthesis, and increased bile acid synthesis. (1) Regarding increased fatty acid uptake, FATP and CD36 are upregulated in MASLD. Although CAV-1 is involved in fat uptake, its role in MASLD remains controversial. (2) Concerning increased de novo lipogenesis, ACLY, ACSS, ACC, FASN, and SCD, key enzymes involved in de novo fatty acid synthesis, are upregulated in MASLD. Among them, SREBP1 can sense cholesterol levels and affect MASLD by transcriptionally regulating key genes involved in hepatic lipid metabolism. SREBP1 induces ACC, FASN, SCD, and other lipid synthesis genes to promote hepatic fatty acid and triglyceride synthesis. SREBP1 has been considered to have great potential as a treatment target for MASLD. (3) Inhibition of fatty acid oxidation can also lead to MASLD. Inhibition of ACSL and CPT-1, key enzymes in lipolysis, can exacerbate hepatic steatosis. Fatty acid oxidation can be regulated by PPARα, and PPARα activation promotes CPT1 expression, thereby enhancing fatty acid β-oxidation. Dysregulated cholesterol metabolism is also involved in the development of MASLD. (4) Increased cholesterol uptake can exacerbate MASLD through increased NPC1L1 expression. (5) Regarding increased cholesterol synthesis, HMGCR, a key enzyme for cholesterol synthesis, is upregulated in MASLD. SM has also been found to play an important role in the progression of MASLD to HCC. (6) Finally, increased bile acid synthesis is involved in the development of MASLD. CYP7A1, a key enzyme involved in bile acid synthesis, has elevated expression in MASLD. Hepatic bile acid synthesis is mainly regulated by FXR, and FXR activation inhibits de novo bile acid synthesis, thereby ameliorating MASLD.

Conclusions

Although much research has investigated the mechanisms of MASLD development, some unanswered questions remain. Peroxisomes are involved in the β-oxidation of extra-long-chain fatty acids, but little research has assessed the connection between peroxisomes and MASLD. Current models of MASLD are mainly based on oleic acid-induced cells and high-fat diet-fed mice, which do not fully capture the dynamic process of MASH fibrosis that can progress to cirrhosis and HCC. Thus, the need for novel, low-cost, and rapid MASLD models for life science research is evident. Despite numerous new drugs, including molecule drugs and CPMs, entering clinical trials in recent years, the treatment of MASLD remains ineffective given the large MASLD population. Lipid metabolism, as an important mechanism in the development of MASLD, has been the primary focus of MASLD treatment. Therefore, the exploration of new drugs and targets that regulate lipid metabolism for MASLD treatment is an area that requires in-depth research.
==== Refs
References

1 Le MH Yeo YH Li X Li J Zou B Wu Y 2019 global nafld prevalence: A systematic review and meta-analysis Clin Gastroenterol Hepatol 2022 20 12 2809 2817.e2828 10.1016/j.cgh.2021.12.002 34890795
2 Younossi ZM Stepanova M Negro F Hallaji S Younossi Y Lam B Nonalcoholic fatty liver disease in lean individuals in the united states Medicine (Baltimore) 2012 91 6 319 327 10.1097/MD.0b013e3182779d49 23117851
3 Zhou J Zhou F Wang W Zhang XJ Ji YX Zhang P Epidemiological features of nafld from 1999 to 2018 in china Hepatology 2020 71 5 1851 1864 10.1002/hep.31150 32012320
4 Younossi ZM Koenig AB Abdelatif D Fazel Y Henry L Wymer M Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 2016 64 1 73 84 10.1002/hep.28431 26707365
5 Eslam M Valenti L Romeo S Genetics and epigenetics of nafld and nash: Clinical impact J Hepatol 2018 68 2 268 279 10.1016/j.jhep.2017.09.003 29122391
6 Qin Y Li B Arumugam S Lu Q Mankash SM Li J M(6)a mrna methylation-directed myeloid cell activation controls progression of nafld and obesity Cell Rep 2021 37 6 109968 10.1016/j.celrep.2021.109968 34758326
7 Yin Q Li Y Zhou Z Li X Li M Liu C Rpa1 controls chromatin architecture and maintains lipid metabolic homeostasis Cell Rep 2022 40 2 111071 10.1016/j.celrep.2022.111071 35830798
8 Hochreuter MY Dall M Treebak JT Barrès R Micrornas in non-alcoholic fatty liver disease: Progress and perspectives Mol Metab 2022 65 101581 10.1016/j.molmet.2022.101581 36028120
9 Leslie T Pawloski L Kallman-Price J Escheik C Hossain N Fang Y Survey of health status, nutrition and geography of food selection of chronic liver disease patients Ann Hepatol 2014 13 5 533 540 25152986
10 Gerber L Otgonsuren M Mishra A Escheik C Birerdinc A Stepanova M Non-alcoholic fatty liver disease (nafld) is associated with low level of physical activity: A population-based study Aliment Pharmacol Ther 2012 36 8 772 781 10.1111/apt.12038 22958053
11 Patel AH Peddu D Amin S Elsaid MI Minacapelli CD Chandler TM Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment J Clin Transl Hepatol 2023 11 2 502 515 10.14218/JCTH.2022.00204 36643037
12 Wong VW Adams LA de Lédinghen V Wong GL Sookoian S Noninvasive biomarkers in nafld and nash - current progress and future promise Nat Rev Gastroenterol Hepatol 2018 15 8 461 478 10.1038/s41575-018-0014-9 29844588
13 Noureddin M Lam J Peterson MR Middleton M Hamilton G Le TA Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials Hepatology 2013 58 6 1930 1940 10.1002/hep.26455 23696515
14 Koo SH Nonalcoholic fatty liver disease: Molecular mechanisms for the hepatic steatosis Clin Mol Hepatol 2013 19 3 210 215 10.3350/cmh.2013.19.3.210 24133660
15 Falcon A Doege H Fluitt A Tsang B Watson N Kay MA Fatp2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-coa synthetase Am J Physiol Endocrinol Metab 2010 299 3 E384 393 10.1152/ajpendo.00226.2010 20530735
16 Perez VM Gabell J Behrens M Wase N DiRusso CC Black PN Deletion of fatty acid transport protein 2 (fatp2) in the mouse liver changes the metabolic landscape by increasing the expression of pparα-regulated genes J Biol Chem 2020 295 17 5737 5750 10.1074/jbc.RA120.012730 32188695
17 Doege H Grimm D Falcon A Tsang B Storm TA Xu H Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia J Biol Chem 2008 283 32 22186 22192 10.1074/jbc.M803510200 18524776
18 Enooku K Tsutsumi T Kondo M Fujiwara N Sasako T Shibahara J Hepatic fatp5 expression is associated with histological progression and loss of hepatic fat in nafld patients J Gastroenterol 2020 55 2 227 243 10.1007/s00535-019-01633-2 31602526
19 Koonen DP Jacobs RL Febbraio M Young ME Soltys CL Ong H Increased hepatic cd36 expression contributes to dyslipidemia associated with diet-induced obesity Diabetes 2007 56 12 2863 2871 10.2337/db07-0907 17728375
20 Zhao L Zhang C Luo X Wang P Zhou W Zhong S Cd36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis J Hepatol 2018 69 3 705 717 10.1016/j.jhep.2018.04.006 29705240
21 Zeng S Wu F Chen M Li Y You M Zhang Y Inhibition of fatty acid translocase (fat/cd36) palmitoylation enhances hepatic fatty acid β-oxidation by increasing its localization to mitochondria and interaction with long-chain acyl-coa synthetase 1 Antioxid Redox Signal 2022 36 16-18 1081 1100 10.1089/ars.2021.0157 35044230
22 Wang J Hao JW Wang X Guo H Sun HH Lai XY Dhhc4 and dhhc5 facilitate fatty acid uptake by palmitoylating and targeting cd36 to the plasma membrane Cell Rep 2019 26 1 209 221.e205 10.1016/j.celrep.2018.12.022 30605677
23 Hajri T Zaiou M Fungwe TV Ouguerram K Besong S Epigenetic regulation of peroxisome proliferator-activated receptor gamma mediates high-fat diet-induced non-alcoholic fatty liver disease Cells 2021 10 6 1355 10.3390/cells10061355 34072832
24 Yang Z Huang X Zhang J You K Xiong Y Fang J Hepatic dkk1-driven steatosis is cd36 dependent Life Sci Alliance 2023 6 1 e202201665 10.26508/lsa.202201665 36410795
25 Pan X Queiroz J Hussain MM Nonalcoholic fatty liver disease in clock mutant mice J Clin Invest 2020 130 8 4282 4300 10.1172/jci132765 32396530
26 El-Derany MO AbdelHamid SG Upregulation of mir-96-5p by bone marrow mesenchymal stem cells and their exosomes alleviate non-alcoholic steatohepatitis: Emphasis on caspase-2 signaling inhibition Biochem Pharmacol 2021 190 114624 10.1016/j.bcp.2021.114624 34052187
27 Smolka C Schlösser D Hohnloser C Bemtgen X Jänich C Schneider L Mir-100 overexpression attenuates high fat diet induced weight gain, liver steatosis, hypertriglyceridemia and development of metabolic syndrome in mice Mol Med 2021 27 1 101 10.1186/s10020-021-00364-6 34488621
28 Ding D Ye G Lin Y Lu Y Zhang H Zhang X Microrna-26a-cd36 signaling pathway: Pivotal role in lipid accumulation in hepatocytes induced by pm(2.5) liposoluble extracts Environ Pollut 2019 248 269 278 10.1016/j.envpol.2019.01.112 30798028
29 Guo J Fang W Sun L Lu Y Dou L Huang X Ultraconserved element uc.372 drives hepatic lipid accumulation by suppressing mir-195/mir4668 maturation Nat Commun 2018 9 1 612 10.1038/s41467-018-03072-8 29426937
30 Qiu Y Liu S Chen HT Yu CH Teng XD Yao HT Upregulation of caveolin-1 and sr-b1 in mice with non-alcoholic fatty liver disease Hepatobiliary Pancreat Dis Int 2013 12 6 630 636 10.1016/s1499-3872(13)60099-5 24322749
31 Li M Chen D Huang H Wang J Wan X Xu C Caveolin1 protects against diet induced hepatic lipid accumulation in mice PLoS One 2017 12 6 e0178748 10.1371/journal.pone.0178748 28570612
32 Xue W Wang J Jiang W Shi C Wang X Huang Y Caveolin-1 alleviates lipid accumulation in nafld associated with promoting autophagy by inhibiting the akt/mtor pathway Eur J Pharmacol 2020 871 172910 10.1016/j.ejphar.2020.172910 31926991
33 Han M Piorońska W Wang S Nwosu ZC Sticht C Wang S Hepatocyte caveolin-1 modulates metabolic gene profiles and functions in non-alcoholic fatty liver disease Cell Death Dis 2020 11 2 104 10.1038/s41419-020-2295-5 32029710
34 Siculella L Giannotti L Testini M Gnoni GV Damiano F In steatotic cells, atp-citrate lyase mrna is efficiently translated through a cap-independent mechanism, contributing to the stimulation of de novo lipogenesis Int J Mol Sci 2020 21 4 1206 10.3390/ijms21041206 32054087
35 Guo L Guo YY Li BY Peng WQ Chang XX Gao X Enhanced acetylation of atp-citrate lyase promotes the progression of nonalcoholic fatty liver disease J Biol Chem 2019 294 31 11805 11816 10.1074/jbc.RA119.008708 31197036
36 Li K Zhang K Wang H Wu Y Chen N Chen J Hrd1-mediated acly ubiquitination alleviate nafld in db/db mice Metabolism 2021 114 154349 10.1016/j.metabol.2020.154349 32888949
37 Zhao S Jang C Liu J Uehara K Gilbert M Izzo L Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate Nature 2020 579 7800 586 591 10.1038/s41586-020-2101-7 32214246
38 Mao J DeMayo FJ Li H Abu-Elheiga L Gu Z Shaikenov TE Liver-specific deletion of acetyl-coa carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis Proc Natl Acad Sci U S A 2006 103 22 8552 8557 10.1073/pnas.0603115103 16717184
39 Lally JSV Ghoshal S DePeralta DK Moaven O Wei L Masia R Inhibition of acetyl-coa carboxylase by phosphorylation or the inhibitor nd-654 suppresses lipogenesis and hepatocellular carcinoma Cell Metab 2019 29 1 174 182.e175 10.1016/j.cmet.2018.08.020 30244972
40 Hu Y He W Huang Y Xiang H Guo J Che Y Fatty acid synthase-suppressor screening identifies sorting nexin 8 as a therapeutic target for nafld Hepatology 2021 74 5 2508 2525 10.1002/hep.32045 34231239
41 Zhang M Tang Y Tang E Lu W Microrna-103 represses hepatic de novo lipogenesis and alleviates nafld via targeting fasn and scd1 Biochem Biophys Res Commun 2020 524 3 716 722 10.1016/j.bbrc.2020.01.143 32035613
42 Liu Y Lin H Jiang L Shang Q Yin L Lin JD Hepatic slug epigenetically promotes liver lipogenesis, fatty liver disease, and type 2 diabetes J Clin Invest 2020 130 6 2992 3004 10.1172/jci128073 32365055
43 Gao R Li Y Xu Z Zhang F Xu J Hu Y Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease Hepatology 2023 78 6 1800 1815 10.1097/hep.0000000000000279 36651176
44 Shimano H Horton JD Shimomura I Hammer RE Brown MS Goldstein JL Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells J Clin Invest 1997 99 5 846 854 10.1172/jci119248 9062341
45 Bae JY Resistance exercise regulates hepatic lipolytic factors as effective as aerobic exercise in obese mice Int J Environ Res Public Health 2020 17 22 8307 10.3390/ijerph17228307 33182720
46 Dos Santos GF Veras ASC de Freitas MC McCabe J Seraphim PM Teixeira GR Strength training reduces lipid accumulation in liver of obese wistar rats Life Sci 2019 235 116834 10.1016/j.lfs.2019.116834 31493478
47 Li R Li Y Yang X Hu Y Yu H Li Y Reducing vegfb accelerates nafld and insulin resistance in mice via inhibiting ampk signaling pathway J Transl Med 2022 20 1 341 10.1186/s12967-022-03540-2 35907871
48 Luo W Ye L Hu XT Wang MH Wang MX Jin LM Md2 deficiency prevents high-fat diet-induced ampk suppression and lipid accumulation through regulating tbk1 in non-alcoholic fatty liver disease Clin Transl Med 2022 12 3 e777 10.1002/ctm2.777 35343085
49 Jung TW Kyung EJ Kim HC Shin YK Lee SH Park ES Protectin dx ameliorates hepatic steatosis by suppression of endoplasmic reticulum stress via ampk-induced orp150 expression J Pharmacol Exp Ther 2018 365 3 485 493 10.1124/jpet.117.246686 29572342
50 Han J Li E Chen L Zhang Y Wei F Liu J The creb coactivator crtc2 controls hepatic lipid metabolism by regulating srebp1 Nature 2015 524 7564 243 246 10.1038/nature14557 26147081
51 Ma N Wang YK Xu S Ni QZ Zheng QW Zhu B Ppdpf alleviates hepatic steatosis through inhibition of mtor signaling Nat Commun 2021 12 1 3059 10.1038/s41467-021-23285-8 34031390
52 Zeng H Qin H Liao M Zheng E Luo X Xiao A Cd36 promotes de novo lipogenesis in hepatocytes through insig2-dependent srebp1 processing Mol Metab 2022 57 101428 10.1016/j.molmet.2021.101428 34974159
53 Li L Zhang X Ren H Huang X Shen T Tang W Mir-23a/b-3p promotes hepatic lipid accumulation by regulating srebp-1c and fas J Mol Endocrinol 2021 68 1 35 49 10.1530/jme-20-0324 34723832
54 Pan JH Cha H Tang J Lee S Lee SH Le B The role of microrna-33 as a key regulator in hepatic lipogenesis signaling and a potential serological biomarker for nafld with excessive dietary fructose consumption in c57bl/6n mice Food Funct 2021 12 2 656 667 10.1039/d0fo02286a 33404569
55 Liu X Chen S Zhang L Downregulated microrna-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease Am J Physiol Endocrinol Metab 2020 319 1 E34 e42 10.1152/ajpendo.00528.2019 32228319
56 Zhou JP Ren YD Xu QY Song Y Zhou F Chen MY Obesity-induced upregulation of zbtb7a promotes lipid accumulation through srebp1 Biomed Res Int 2020 2020 4087928 10.1155/2020/4087928 31998789
57 Kim YR Lee EJ Shin KO Kim MH Pewzner-Jung Y Lee YM Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced srebp-1 activation is regulated by ceramide synthases Exp Mol Med 2019 51 11 1 16 10.1038/s12276-019-0340-1 31676768
58 Seidu T McWhorter P Myer J Alamgir R Eregha N Bogle D Dht causes liver steatosis via transcriptional regulation of scap in normal weight female mice J Endocrinol 2021 250 2 49 65 10.1530/joe-21-0040 34060475
59 Araki M Nakagawa Y Saito H Yamada Y Han SI Mizunoe Y Hepatocyte- or macrophage-specific srebp-1a deficiency in mice exacerbates methionine- and choline-deficient diet-induced nonalcoholic fatty liver disease Am J Physiol Gastrointest Liver Physiol 2022 323 6 G627 g639 10.1152/ajpgi.00090.2022 36283088
60 Wei G An P Vaid KA Nasser I Huang P Tan L Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer Am J Physiol Gastrointest Liver Physiol 2020 318 1 G174 g188 10.1152/ajpgi.00041.2019 31630534
61 Gabbia D Roverso M Guido M Sacchi D Scaffidi M Carrara M Western diet-induced metabolic alterations affect circulating markers of liver function before the development of steatosis Nutrients 2019 11 7 1602 10.3390/nu11071602 31311123
62 Cheng C Deng X Xu K Increased expression of sterol regulatory element binding protein-2 alleviates autophagic dysfunction in nafld Int J Mol Med 2018 41 4 1877 1886 10.3892/ijmm.2018.3389 29336468
63 Huh JY Reilly SM Abu-Odeh M Murphy AN Mahata SK Zhang J Tank-binding kinase 1 regulates the localization of acyl-coa synthetase acsl1 to control hepatic fatty acid oxidation Cell Metab 2020 32 6 1012 1027.e1017 10.1016/j.cmet.2020.10.010 33152322
64 Duan J Wang Z Duan R Yang C Zhao R Feng Q Therapeutic targeting of hepatic acsl4 ameliorates nash in mice Hepatology 2022 75 1 140 153 10.1002/hep.32148 34510514
65 Singh AB Kan CFK Kraemer FB Sobel RA Liu J Liver-specific knockdown of long-chain acyl-coa synthetase 4 reveals its key role in vldl-tg metabolism and phospholipid synthesis in mice fed a high-fat diet Am J Physiol Endocrinol Metab 2019 316 5 E880 e894 10.1152/ajpendo.00503.2018 30721098
66 Wei S Qiu T Wang N Yao X Jiang L Jia X Ferroptosis mediated by the interaction between mfn2 and ireα promotes arsenic-induced nonalcoholic steatohepatitis Environ Res 2020 188 109824 10.1016/j.envres.2020.109824 32593899
67 Sen P Kan CFK Singh AB Rius M Kraemer FB Sztul E Identification of p115 as a novel acsl4 interacting protein and its role in regulating acsl4 degradation J Proteomics 2020 229 103926 10.1016/j.jprot.2020.103926 32736139
68 Bowman TA O’Keeffe KR D’Aquila T Yan QW Griffin JD Killion EA Acyl coa synthetase 5 (acsl5) ablation in mice increases energy expenditure and insulin sensitivity and delays fat absorption Mol Metab 2016 5 3 210 220 10.1016/j.molmet.2016.01.001 26977393
69 Luo Y Chen Q Zou J Fan J Li Y Luo Z Chronic intermittent hypoxia exposure alternative to exercise alleviates high-fat-diet-induced obesity and fatty liver Int J Mol Sci 2022 23 9 5209 10.3390/ijms23095209 35563600
70 Zheng F Cai Y Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating ppar-γ and genes involved in the beta-oxidation of fatty acids in apoe-ko mice fed a high-fat diet Lipids Health Dis 2019 18 1 6 10.1186/s12944-018-0933-z 30611282
71 Ahmed EA El-Derany MO Anwar AM Saied EM Magdeldin S Metabolomics and lipidomics screening reveal reprogrammed signaling pathways toward cancer development in non-alcoholic steatohepatitis Int J Mol Sci 2022 24 1 210 10.3390/ijms24010210 36613653
72 Heinecke F Mazzucco MB Fornes D Roberti S Jawerbaum A White V The offspring from rats fed a fatty diet display impairments in the activation of liver peroxisome proliferator activated receptor alpha and features of fatty liver disease Mol Cell Endocrinol 2020 511 110818 10.1016/j.mce.2020.110818 32298755
73 Smati S Polizzi A Fougerat A Ellero-Simatos S Blum Y Lippi Y Integrative study of diet-induced mouse models of nafld identifies pparα as a sexually dimorphic drug target Gut 2022 71 4 807 821 10.1136/gutjnl-2020-323323 33903148
74 Silva-Veiga FM Miranda CS Vasques-Monteiro IML Souza-Tavares H Martins FF Daleprane JB Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice World J Gastroenterol 2022 28 17 1814 1829 10.3748/wjg.v28.i17.1814 35633911
75 Yan T Luo Y Yan N Hamada K Zhao N Xia Y Intestinal peroxisome proliferator-activated receptor α-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis Hepatology 2023 77 1 239 255 10.1002/hep.32538 35460276
76 Chen K Chen X Xue H Zhang P Fang W Chen X Coenzyme q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the ampk pathway Food Funct 2019 10 2 814 823 10.1039/c8fo01236a 30675881
77 Du X Osoro EK Chen Q Yan X Gao D Wu L Pdcd4 promotes lipid deposition by attenuating pparα-mediated fatty acid oxidation in hepatocytes Mol Cell Endocrinol 2022 545 111562 10.1016/j.mce.2022.111562 35051553
78 Wei X Zhang J Tang M Wang X Fan N Peng Y Fat mass and obesity-associated protein promotes liver steatosis by targeting pparα Lipids Health Dis 2022 21 1 29 10.1186/s12944-022-01640-y 35282837
79 Qin G Wang GZ Guo DD Bai RX Wang M Du SY Deletion of smad4 reduces hepatic inflammation and fibrogenesis during nonalcoholic steatohepatitis progression J Dig Dis 2018 19 5 301 313 10.1111/1751-2980.12599 29696816
80 Ko CW Qu J Black DD Tso P Regulation of intestinal lipid metabolism: Current concepts and relevance to disease Nat Rev Gastroenterol Hepatol 2020 17 3 169 183 10.1038/s41575-019-0250-7 32015520
81 Toyoda Y Takada T Yamanashi Y Suzuki H Pathophysiological importance of bile cholesterol reabsorption: Hepatic npc1l1-exacerbated steatosis and decreasing vldl-tg secretion in mice fed a high-fat diet Lipids Health Dis 2019 18 1 234 10.1186/s12944-019-1179-0 31883528
82 Yamanashi Y Takada T Tanaka Y Ogata Y Toyoda Y Ito SM Hepatic niemann-pick c1-like 1 exacerbates non-alcoholic fatty liver disease by re-absorbing specific biliary oxysterols Biomed Pharmacother 2022 156 113877 10.1016/j.biopha.2022.113877 36270257
83 Min HK Kapoor A Fuchs M Mirshahi F Zhou H Maher J Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease Cell Metab 2012 15 5 665 674 10.1016/j.cmet.2012.04.004 22560219
84 Li T Yan H Geng Y Shi H Li H Wang S Target genes associated with lipid and glucose metabolism in non-alcoholic fatty liver disease Lipids Health Dis 2019 18 1 211 10.1186/s12944-019-1154-9 31805951
85 Liu MX Gao M Li CZ Yu CZ Yan H Peng C Dicer1/mir-29/hmgcr axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis Acta Pharmacol Sin 2017 38 5 660 671 10.1038/aps.2016.158 28112179
86 Liang JQ Teoh N Xu L Pok S Li X Chu ESH Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling Nat Commun 2018 9 1 4490 10.1038/s41467-018-06931-6 30367044
87 Liu D Wong CC Fu L Chen H Zhao L Li C Squalene epoxidase drives nafld-induced hepatocellular carcinoma and is a pharmaceutical target Sci Transl Med 2018 10 437 eaap9840 10.1126/scitranslmed.aap9840 29669855
88 Liu D Wong CC Zhou Y Li C Chen H Ji F Squalene epoxidase induces nonalcoholic steatohepatitis via binding to carbonic anhydrase iii and is a therapeutic target Gastroenterology 2021 160 7 2467 2482.e2463 10.1053/j.gastro.2021.02.051 33647280
89 Sun H Li L Li W Yang F Zhang Z Liu Z P53 transcriptionally regulates sqle to repress cholesterol synthesis and tumor growth EMBO Rep 2021 22 10 e52537 10.15252/embr.202152537 34459531
90 Jia X Zhai T Integrated analysis of multiple microarray studies to identify novel gene signatures in non-alcoholic fatty liver disease Front Endocrinol (Lausanne) 2019 10 599 10.3389/fendo.2019.00599 31551930
91 Wu C Zhou Y Wang M Dai G Liu X Lai L Bioinformatics analysis explores potential hub genes in nonalcoholic fatty liver disease Front Genet 2021 12 772487 10.3389/fgene.2021.772487 34777484
92 Jiao N Baker SS Chapa-Rodriguez A Liu W Nugent CA Tsompana M Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in nafld Gut 2018 67 10 1881 1891 10.1136/gutjnl-2017-314307 28774887
93 Suga T Yamaguchi H Ogura J Shoji S Maekawa M Mano N Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis Toxicol Appl Pharmacol 2019 379 114664 10.1016/j.taap.2019.114664 31306673
94 Clifford BL Sedgeman LR Williams KJ Morand P Cheng A Jarrett KE Fxr activation protects against nafld via bile-acid-dependent reductions in lipid absorption Cell Metab 2021 33 8 1671 1684.e1674 10.1016/j.cmet.2021.06.012 34270928
95 Deng W Fan W Tang T Wan H Zhao S Tan Y Farnesoid x receptor deficiency induces hepatic lipid and glucose metabolism disorder via regulation of pyruvate dehydrogenase kinase 4 Oxid Med Cell Longev 2022 2022 3589525 10.1155/2022/3589525 35251469
96 Xu W Cui C Cui C Chen Z Zhang H Cui Q Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid x receptor Hepatology 2022 76 6 1794 1810 10.1002/hep.32577 35586979
97 Fan L Lai R Ma N Dong Y Li Y Wu Q Mir-552-3p modulates transcriptional activities of fxr and lxr to ameliorate hepatic glycolipid metabolism disorder J Hepatol 2021 74 1 8 19 10.1016/j.jhep.2020.07.048 32818571
98 Kokkorakis M Boutari C Hill MA Kotsis V Loomba R Sanyal AJ Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges Metabolism 2024 154 155835 10.1016/j.metabol.2024.155835 38508373
99 Krishnan A Schneider CV Hadi Y Mukherjee D AlShehri B Alqahtani SA Cardiovascular and mortality outcomes with glp-1 receptor agonists vs other glucose-lowering drugs in individuals with nafld and type 2 diabetes: A large population-based matched cohort study Diabetologia 2024 67 3 483 493 10.1007/s00125-023-06057-5 38117293
100 Liao C Liang X Zhang X Li Y The effects of glp-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis PLoS One 2023 18 8 e0289616 10.1371/journal.pone.0289616 37616255
101 Gu Y Sun L Zhang W Kong T Zhou R He Y Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (sglt-2) inhibitor and 4 glucagon-like peptide-1 (glp-1) receptor agonist drugs in non-alcoholic fatty liver disease: A grade-assessed systematic review and network meta-analysis of randomized controlled trials Front Pharmacol 2023 14 1102792 10.3389/fphar.2023.1102792 36992825
102 Gu Y Sun L He Y Yang L Deng C Zhou R Comparative efficacy of glucagon-like peptide 1 (glp-1) receptor agonists, pioglitazone and vitamin e for liver histology among patients with nonalcoholic fatty liver disease: Systematic review and pilot network meta-analysis of randomized controlled trials Expert Rev Gastroenterol Hepatol 2023 17 3 273 282 10.1080/17474124.2023.2172397 36689199
103 Romero-Gómez M Armstrong MJ Funuyet-Salas J Mangla KK Ladelund S Sejling AS Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial Aliment Pharmacol Ther 2023 58 4 395 403 10.1111/apt.17598 37328931
104 Yuan X Gao Z Yang C Duan K Ren L Song G Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: A network meta-analysis Front Endocrinol (Lausanne) 2023 14 1170881 10.3389/fendo.2023.1170881 37342259
105 Mao T Zhang C Yang S Bi Y Li M Yu J Semaglutide alters gut microbiota and improves nafld in db/db mice Biochem Biophys Res Commun 2024 710 149882 10.1016/j.bbrc.2024.149882 38583231
106 Kim ER Park JS Kim JH Oh JY Oh IJ Choi DH A glp-1/glp-2 receptor dual agonist to treat nash: Targeting the gut-liver axis and microbiome Hepatology 2022 75 6 1523 1538 10.1002/hep.32235 34773257
107 Romero-Gómez M Lawitz E Shankar RR Chaudhri E Liu J Lam RLH A phase iia active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease J Hepatol 2023 79 4 888 897 10.1016/j.jhep.2023.05.013 37355043
108 Nestor JJ Parkes D Feigh M Suschak JJ Harris MS Effects of alt-801, a glp-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis Sci Rep 2022 12 1 6666 10.1038/s41598-022-10577-2 35461369
109 Monfeuga T Norlin J Bugge A Gaalsgaard ED Prada-Medina CA Latta M Evaluation of long acting glp1r/gcgr agonist in a dio and biopsy-confirmed mouse model of nash suggest a beneficial role of glp-1/glucagon agonism in nash patients Mol Metab 2024 79 101850 10.1016/j.molmet.2023.101850 38065435
110 Desjardins EM Wu J Lavoie DCT Ahmadi E Townsend LK Morrow MR Combination of an acly inhibitor with a glp-1r agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice Cell Rep Med 2023 4 9 101193 10.1016/j.xcrm.2023.101193 37729871
111 Alkhouri N Herring R Kabler H Kayali Z Hassanein T Kohli A Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase ii trial J Hepatol 2022 77 3 607 618 10.1016/j.jhep.2022.04.003 35439567
112 Xue H Xing HJ Wang B Fu C Zhang YS Qiao X Cinchonine, a potential oral small-molecule glucagon-like peptide-1 receptor agonist, lowers blood glucose and ameliorates non-alcoholic steatohepatitis Drug Des Devel Ther 2023 17 1417 1432 10.2147/dddt.S404055 37197367
113 Mahalingam S Bellamkonda R Arumugam MK Perumal SK Yoon J Casey C Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease Biochem Pharmacol 2023 213 115613 10.1016/j.bcp.2023.115613 37209859
114 Kuchay MS Krishan S Mishra SK Choudhary NS Singh MK Wasir JS Effect of dulaglutide on liver fat in patients with type 2 diabetes and nafld: Randomised controlled trial (d-lift trial) Diabetologia 2020 63 11 2434 2445 10.1007/s00125-020-05265-7 32865597
115 Liu L Yan H Xia M Zhao L Lv M Zhao N Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes Diabetes Metab Res Rev 2020 36 5 e3292 10.1002/dmrr.3292 31955491
116 Khoo J Hsiang JC Taneja R Koo SH Soon GH Kam CJ Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease Liver Int 2019 39 5 941 949 10.1111/liv.14065 30721572
117 Armstrong MJ Hull D Guo K Barton D Hazlehurst JM Gathercole LL Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis J Hepatol 2016 64 2 399 408 10.1016/j.jhep.2015.08.038 26394161
118 Khoo J Hsiang J Taneja R Law NM Ang TL Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial Diabetes Obes Metab 2017 19 12 1814 1817 10.1111/dom.13007 28503750
119 Petit JM Cercueil JP Loffroy R Denimal D Bouillet B Fourmont C Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The lira-nafld study J Clin Endocrinol Metab 2017 102 2 407 415 10.1210/jc.2016-2775 27732328
120 Smits MM Tonneijck L Muskiet MH Kramer MH Pouwels PJ Pieters-van den Bos IC Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: A randomised placebo-controlled trial Diabetologia 2016 59 12 2588 2593 10.1007/s00125-016-4100-7 27627981
121 Newsome PN Buchholtz K Cusi K Linder M Okanoue T Ratziu V A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis N Engl J Med 2021 384 12 1113 1124 10.1056/NEJMoa2028395 33185364
122 Flint A Andersen G Hockings P Johansson L Morsing A Sundby Palle M Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging Aliment Pharmacol Ther 2021 54 9 1150 1161 10.1111/apt.16608 34570916
123 Farage AE Abdo W Osman A Abdel-Kareem MA Hakami ZH Alsulimani A Betulin prevents high fat diet-induced non-alcoholic fatty liver disease by mitigating oxidative stress and upregulating nrf2 and sirt1 in rats Life Sci 2023 322 121688 10.1016/j.lfs.2023.121688 37030617
124 Kim KD Jung HY Ryu HG Kim B Jeon J Yoo HY Betulinic acid inhibits high-fat diet-induced obesity and improves energy balance by activating ampk Nutr Metab Cardiovasc Dis 2019 29 4 409 420 10.1016/j.numecd.2018.12.001 30799179
125 Mu Q Wang H Tong L Fang Q Xiang M Han L Betulinic acid improves nonalcoholic fatty liver disease through yy1/fas signaling pathway Faseb j 2020 34 9 13033 13048 10.1096/fj.202000546R 32777136
126 Quan HY Kim DY Kim SJ Jo HK Kim GW Chung SH Betulinic acid alleviates non-alcoholic fatty liver by inhibiting srebp1 activity via the ampk-mtor-srebp signaling pathway Biochem Pharmacol 2013 85 9 1330 1340 10.1016/j.bcp.2013.02.007 23435355
127 Bitter A Nüssler AK Thasler WE Klein K Zanger UM Schwab M Human sterol regulatory element-binding protein 1a contributes significantly to hepatic lipogenic gene expression Cell Physiol Biochem 2015 35 2 803 815 10.1159/000369739 25634759
128 Bates J Vijayakumar A Ghoshal S Marchand B Yi S Kornyeyev D Acetyl-coa carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation J Hepatol 2020 73 4 896 905 10.1016/j.jhep.2020.04.037 32376414
129 Goedeke L Bates J Vatner DF Perry RJ Wang T Ramirez R Acetyl-coa carboxylase inhibition reverses nafld and hepatic insulin resistance but promotes hypertriglyceridemia in rodents Hepatology 2018 68 6 2197 2211 10.1002/hep.30097 29790582
130 Lawitz EJ Coste A Poordad F Alkhouri N Loo N McColgan BJ Acetyl-coa carboxylase inhibitor gs-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 2018 16 12 1983 1991.e1983 10.1016/j.cgh.2018.04.042 29705265
131 Loomba R Kayali Z Noureddin M Ruane P Lawitz EJ Bennett M Gs-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease Gastroenterology 2018 155 5 1463 1473.e1466 10.1053/j.gastro.2018.07.027 30059671
132 Dandan M Han J Mann S Kim R Li K Mohammed H Acetyl-coa carboxylase inhibitor increases ldl-apob production rate in nash with cirrhosis: Prevention by fenofibrate J Lipid Res 2023 64 3 100339 10.1016/j.jlr.2023.100339 36737040
133 Lawitz EJ Bhandari BR Ruane PJ Kohli A Harting E Ding D Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat Clin Gastroenterol Hepatol 2023 21 1 143 152.e143 10.1016/j.cgh.2021.12.044 34999207
134 Tamura YO Sugama J Iwasaki S Sasaki M Yasuno H Aoyama K Selective acetyl-coa carboxylase 1 inhibitor improves hepatic steatosis and hepatic fibrosis in a preclinical nonalcoholic steatohepatitis model J Pharmacol Exp Ther 2021 379 3 280 289 10.1124/jpet.121.000786 34535562
135 Ross TT Crowley C Kelly KL Rinaldi A Beebe DA Lech MP Acetyl-coa carboxylase inhibition improves multiple dimensions of nash pathogenesis in model systems Cell Mol Gastroenterol Hepatol 2020 10 4 829 851 10.1016/j.jcmgh.2020.06.001 32526482
136 Gao YS Qian MY Wei QQ Duan XB Wang SL Hu HY Wz66, a novel acetyl-coa carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (nash) in mice Acta Pharmacol Sin 2020 41 3 336 347 10.1038/s41401-019-0310-0 31645659
137 Loomba R Mohseni R Lucas KJ Gutierrez JA Perry RG Trotter JF Tvb-2640 (fasn inhibitor) for the treatment of nonalcoholic steatohepatitis: Fascinate-1, a randomized, placebo-controlled phase 2a trial Gastroenterology 2021 161 5 1475 1486 10.1053/j.gastro.2021.07.025 34310978
138 Beysen C Schroeder P Wu E Brevard J Ribadeneira M Lu W Inhibition of fatty acid synthase with ft-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials Diabetes Obes Metab 2021 23 3 700 710 10.1111/dom.14272 33289350
139 Xu S Wu X Wang S Xu M Fang T Ma X Trim56 protects against nonalcoholic fatty liver disease by promoting the degradation of fatty acid synthase J Clin Invest 2024 134 5 e166149 10.1172/jci166149 38206764
140 Kurikawa N Takagi T Wakimoto S Uto Y Terashima H Kono K A novel inhibitor of stearoyl-coa desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis Biol Pharm Bull 2013 36 2 259 267 10.1248/bpb.b12-00702 23370355
141 Zhou Y Zhong L Yu S Shen W Cai C Yu H Inhibition of stearoyl-coenzyme a desaturase 1 ameliorates hepatic steatosis by inducing ampk-mediated lipophagy Aging (Albany NY) 2020 12 8 7350 7362 10.18632/aging.103082 32324591
142 Jiang S Uddin MJ Yu X Piao L Dorotea D Oh GT Peroxisomal fitness: A potential protective mechanism of fenofibrate against high fat diet-induced non-alcoholic fatty liver disease in mice Diabetes Metab J 2022 46 6 829 842 10.4093/dmj.2021.0274 35746892
143 Guru B Tamrakar AK Manjula SN Prashantha Kumar BR Novel dual pparα/γ agonists protect against liver steatosis and improve insulin sensitivity while avoiding side effects Eur J Pharmacol 2022 935 175322 10.1016/j.ejphar.2022.175322 36228743
144 Grobbee EJ de Jong VD Schrieks IC Tushuizen ME Holleboom AG Tardif JC Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the ppar-α/γ agonist aleglitazar PLoS One 2022 17 11 e0277706 10.1371/journal.pone.0277706 36378671
145 Feng Z Xiang J Liu H Li J Xu X Sun G Design, synthesis, and biological evaluation of triazolone derivatives as potent pparα/δ dual agonists for the treatment of nonalcoholic steatohepatitis J Med Chem 2022 65 3 2571 2592 10.1021/acs.jmedchem.1c02002 35060744
146 Zhou Z Ren Q Jiao S Cai Z Geng X Deng L Discovery of new and highly effective quadruple ffa1 and pparα/γ/δ agonists as potential anti-fatty liver agents Eur J Med Chem 2022 229 114061 10.1016/j.ejmech.2021.114061 34954593
147 Ratziu V Harrison SA Francque S Bedossa P Lehert P Serfaty L Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening Gastroenterology 2016 150 5 1147 1159.e1145 10.1053/j.gastro.2016.01.038 26874076
148 Francque SM Bedossa P Ratziu V Anstee QM Bugianesi E Sanyal AJ A randomized, controlled trial of the pan-ppar agonist lanifibranor in nash N Engl J Med 2021 385 17 1547 1558 10.1056/NEJMoa2036205 34670042
149 Gawrieh S Noureddin M Loo N Mohseni R Awasty V Cusi K Saroglitazar, a ppar-α/γ agonist, for treatment of nafld: A randomized controlled double-blind phase 2 trial Hepatology 2021 74 4 1809 1824 10.1002/hep.31843 33811367
150 Siddiqui MS Idowu MO Parmar D Borg BB Denham D Loo NM A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 2021 19 12 2670 2672 10.1016/j.cgh.2020.10.051 33152542
151 Chianelli D Rucker PV Roland J Tully DC Nelson J Liu X Nidufexor (lmb763), a novel fxr modulator for the treatment of nonalcoholic steatohepatitis J Med Chem 2020 63 8 3868 3880 10.1021/acs.jmedchem.9b01621 31940200
152 Patel K Harrison SA Elkhashab M Trotter JF Herring R Rojter SE Cilofexor, a nonsteroidal fxr agonist, in patients with noncirrhotic nash: A phase 2 randomized controlled trial Hepatology 2020 72 1 58 71 10.1002/hep.31205 32115759
153 Ratziu V Rinella ME Neuschwander-Tetri BA Lawitz E Denham D Kayali Z Edp-305 in patients with nash: A phase ii double-blind placebo-controlled dose-ranging study J Hepatol 2022 76 3 506 517 10.1016/j.jhep.2021.10.018 34740705
154 Qin T Gao X Lei L Zhang W Feng J Wang X Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as fxr agonists for nafld Eur J Med Chem 2023 245 Pt 1 114903 10.1016/j.ejmech.2022.114903 36375336
155 Li J Liu M Li Y Sun DD Shu Z Tan Q Discovery and optimization of non-bile acid fxr agonists as preclinical candidates for the treatment of nonalcoholic steatohepatitis J Med Chem 2020 63 21 12748 12772 10.1021/acs.jmedchem.0c01065 32991173
156 Harrison SA Bashir MR Lee KJ Shim-Lopez J Lee J Wagner B A structurally optimized fxr agonist, met409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis J Hepatol 2021 75 1 25 33 10.1016/j.jhep.2021.01.047 33581174
157 Shim S Krishnaiah M Sankham MR Kim I Lee Y Shin I Discovery of (e)-3-(3-((2-cyano-4′-dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic acid methyl ester, an intestine-specific, fxr partial agonist for the treatment of nonalcoholic steatohepatitis J Med Chem 2022 65 14 9974 10000 10.1021/acs.jmedchem.2c00641 35797110
158 Nara SJ Jogi S Cheruku S Kandhasamy S Jaipuri F Kathi PK Discovery of bms-986339, a pharmacologically differentiated farnesoid x receptor agonist for the treatment of nonalcoholic steatohepatitis J Med Chem 2022 65 13 8948 8960 10.1021/acs.jmedchem.2c00165 35704802
159 Younis IR Kirby BJ Billin AN Xiao D Song Q Watkins TR Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal farnesoid x receptor agonist, in healthy volunteers Clin Transl Sci 2023 16 3 536 547 10.1111/cts.13469 36573450
160 Mudaliar S Henry RR Sanyal AJ Morrow L Marschall HU Kipnes M Efficacy and safety of the farnesoid x receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 2013 145 3 574 582.e571 10.1053/j.gastro.2013.05.042 23727264
161 Sanyal AJ Lopez P Lawitz EJ Lucas KJ Loeffler J Kim W Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a/b trial Nat Med 2023 29 2 392 400 10.1038/s41591-022-02200-8 36797481
162 Ratziu V Harrison SA Loustaud-Ratti V Bureau C Lawitz E Abdelmalek M Hepatic and renal improvements with fxr agonist vonafexor in individuals with suspected fibrotic nash J Hepatol 2023 78 3 479 492 10.1016/j.jhep.2022.10.023 36334688
163 Ran LS Wu YZ Gan YW Wang HL Wu LJ Zheng CM Andrographolide ameliorates hepatic steatosis by suppressing fatp2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease J Nat Med 2023 77 1 73 86 10.1007/s11418-022-01647-w 36115008
164 Li P Zhang R Wang M Chen Y Chen Z Ke X Baicalein prevents fructose-induced hepatic steatosis in rats: In the regulation of fatty acid de novo synthesis, fatty acid elongation and fatty acid oxidation Front Pharmacol 2022 13 917329 10.3389/fphar.2022.917329 35847050
165 Sun W Liu P Wang T Wang X Zheng W Li J Baicalein reduces hepatic fat accumulation by activating ampk in oleic acid-induced hepg2 cells and high-fat diet-induced non-insulin-resistant mice Food Funct 2020 11 1 711 721 10.1039/c9fo02237f 31909773
166 Li QP Dou YX Huang ZW Chen HB Li YC Chen JN Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats Phytomedicine 2021 85 153550 10.1016/j.phymed.2021.153550 33831691
167 Shan MY Dai Y Ren XD Zheng J Zhang KB Chen B Berberine mitigates nonalcoholic hepatic steatosis by downregulating sirt1-foxo1-srebp2 pathway for cholesterol synthesis J Integr Med 2021 19 6 545 554 10.1016/j.joim.2021.09.003 34686466
168 Sharma A Anand SK Singh N Dwarkanath A Dwivedi UN Kakkar P Berbamine induced activation of the sirt1/lkb1/ampk signaling axis attenuates the development of hepatic steatosis in high-fat diet-induced nafld rats Food Funct 2021 12 2 892 909 10.1039/d0fo02501a 33411880
169 Yu M Alimujiang M Hu L Liu F Bao Y Yin J Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex i in gut and liver Int J Biol Sci 2021 17 7 1693 1707 10.7150/ijbs.54604 33994854
170 Zhang YP Deng YJ Tang KR Chen RS Liang S Liang YJ Berberine ameliorates high-fat diet-induced non-alcoholic fatty liver disease in rats via activation of sirt3/ampk/acc pathway Curr Med Sci 2019 39 1 37 43 10.1007/s11596-019-1997-3 30868489
171 Lee M Nam SH Yoon HG Kim S You Y Choi KC Fermented curcuma longa l. Prevents alcoholic fatty liver disease in mice by regulating cyp2e1, srebp-1c, and ppar-α J Med Food 2022 25 4 456 463 10.1089/jmf.2021.K.0098 35438556
172 Mun J Kim S Yoon HG You Y Kim OK Choi KC Water extract of curcuma longa l. Ameliorates non-alcoholic fatty liver disease Nutrients 2019 11 10 2536 10.3390/nu11102536 31640183
173 Sun Q Niu Q Guo Y Zhuang Y Li X Liu J Regulation on citrate influx and metabolism through inhibiting slc13a5 and acly: A novel mechanism mediating the therapeutic effects of curcumin on nafld J Agric Food Chem 2021 69 31 8714 8725 10.1021/acs.jafc.1c03105 34323067
174 Poornima MS Sindhu G Billu A Sruthi CR Nisha P Gogoi P Pretreatment of hydroethanolic extract of dillenia indica l. Attenuates oleic acid induced nafld in hepg2 cells via modulating sirt-1/p-lkb-1/ampk, hmgcr & ppar-α signaling pathways J Ethnopharmacol 2022 292 115237 10.1016/j.jep.2022.115237 35351574
175 Le TNH Choi HJ Jun HS Ethanol extract of liriope platyphylla root attenuates non-alcoholic fatty liver disease in high-fat diet-induced obese mice via regulation of lipogenesis and lipid uptake Nutrients 2021 13 10 3338 10.3390/nu13103338 34684339
176 Ma K Sheng W Gao R Feng J Huang W Cui L Ethanolic extract of root from arctium lappa l ameliorates obesity and hepatic steatosis in rats by regulating the ampk/acc/cpt-1 pathway J Food Biochem 2022 46 12 e14455 10.1111/jfbc.14455 36183168
177 Liu W Shang J Deng Y Han X Chen Y Wang S Network pharmacology analysis on mechanism of jian pi qing gan yin decoction ameliorating high fat diet-induced non-alcoholic fatty liver disease and validated in vivo J Ethnopharmacol 2022 295 115382 10.1016/j.jep.2022.115382 35577161
178 Zhang J Du H Shen M Zhao Z Ye X Kangtaizhi granule alleviated nonalcoholic fatty liver disease in high-fat diet-fed rats and hepg2 cells via ampk/mtor signaling pathway J Immunol Res 2020 2020 3413186 10.1155/2020/3413186 32884949
179 Li Y Yang M Lin H Yan W Deng G Ye H Limonin alleviates non-alcoholic fatty liver disease by reducing lipid accumulation, suppressing inflammation and oxidative stress Front Pharmacol 2021 12 801730 10.3389/fphar.2021.801730 35046824
180 Wang SW Lan T Chen HF Sheng H Xu CY Xu LF Limonin, an ampk activator, inhibits hepatic lipid accumulation in high fat diet fed mice Front Pharmacol 2022 13 833705 10.3389/fphar.2022.833705 35140621
181 Yang Y Wu Y Zou J Wang YH Xu MX Huang W Naringenin attenuates non-alcoholic fatty liver disease by enhancing energy expenditure and regulating autophagy via ampk Front Pharmacol 2021 12 687095 10.3389/fphar.2021.687095 34163366
182 Hao R Shan S Yang D Zhang H Sun Y Li Z Peonidin-3-o-glucoside from purple corncob ameliorates nonalcoholic fatty liver disease by regulating mitochondrial and lysosome functions to reduce oxidative stress and inflammation Nutrients 2023 15 2 372 10.3390/nu15020372 36678243
183 Li YC Qiao JY Wang BY Bai M Shen JD Cheng YX Paeoniflorin ameliorates fructose-induced insulin resistance and hepatic steatosis by activating lkb1/ampk and akt pathways Nutrients 2018 10 8 1024 10.3390/nu10081024 30081580
184 Pham TH Lee GH Jin SW Lee SY Han EH Kim ND Puerarin attenuates hepatic steatosis via g-protein-coupled estrogen receptor-mediated calcium and sirt1 signaling pathways Phytother Res 2022 36 9 3601 3618 10.1002/ptr.7526 35871535
185 Zhou J Zhang N Aldhahrani A Soliman MM Zhang L Zhou F Puerarin ameliorates nonalcoholic fatty liver in rats by regulating hepatic lipid accumulation, oxidative stress, and inflammation Front Immunol 2022 13 956688 10.3389/fimmu.2022.956688 35958617
186 Gu Y Duan S Ding M Zheng Q Fan G Li X Saikosaponin d attenuates metabolic associated fatty liver disease by coordinately tuning pparα and insig/srebp1c pathway Phytomedicine 2022 103 154219 10.1016/j.phymed.2022.154219 35691075
187 Li X Ge J Li Y Cai Y Zheng Q Huang N Integrative lipidomic and transcriptomic study unravels the therapeutic effects of saikosaponins a and d on non-alcoholic fatty liver disease Acta Pharm Sin B 2021 11 11 3527 3541 10.1016/j.apsb.2021.03.018 34900534
